Compare Piramal Healthcare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs BIOCON - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES BIOCON PIRAMAL ENTERPRISES/
BIOCON
 
P/E (TTM) x 19.0 17.4 109.0% View Chart
P/BV x 1.2 2.7 44.7% View Chart
Dividend Yield % 1.5 0.4 342.2%  

Financials

 PIRAMAL ENTERPRISES   BIOCON
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
BIOCON
Mar-18
PIRAMAL ENTERPRISES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs3,3031,188 278.0%   
Low Rs1,797305 589.1%   
Sales per share (Unadj.) Rs716.568.7 1,042.5%  
Earnings per share (Unadj.) Rs79.77.6 1,055.4%  
Cash flow per share (Unadj.) Rs107.914.0 772.4%  
Dividends per share (Unadj.) Rs28.001.00 2,800.0%  
Dividend yield (eoy) %1.10.1 819.8%  
Book value per share (Unadj.) Rs1,477.586.3 1,711.2%  
Shares outstanding (eoy) m184.45600.00 30.7%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x3.610.9 32.8%   
Avg P/E ratio x32.098.9 32.4%  
P/CF ratio (eoy) x23.653.4 44.2%  
Price / Book Value ratio x1.78.6 20.0%  
Dividend payout %35.113.2 265.3%   
Avg Mkt Cap Rs m470,292447,900 105.0%   
No. of employees `0007.86.1 127.2%   
Total wages/salary Rs m22,5049,311 241.7%   
Avg. sales/employee Rs Th16,899.46,705.8 252.0%   
Avg. wages/employee Rs Th2,877.71,514.2 190.0%   
Avg. net profit/employee Rs Th1,879.9736.9 255.1%   
INCOME DATA
Net Sales Rs m132,15341,234 320.5%  
Other income Rs m3,1282,062 151.7%   
Total revenues Rs m135,28143,296 312.5%   
Gross profit Rs m66,2908,291 799.5%  
Depreciation Rs m5,2023,851 135.1%   
Interest Rs m44,097615 7,170.3%   
Profit before tax Rs m20,1195,887 341.7%   
Minority Interest Rs m3,194213 1,499.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,569 548.8%   
Profit after tax Rs m14,7014,531 324.5%  
Gross profit margin %50.220.1 249.5%  
Effective tax rate %42.826.7 160.6%   
Net profit margin %11.111.0 101.2%  
BALANCE SHEET DATA
Current assets Rs m122,74241,486 295.9%   
Current liabilities Rs m310,81021,413 1,451.5%   
Net working cap to sales %-142.348.7 -292.3%  
Current ratio x0.41.9 20.4%  
Inventory Days Days2364 36.1%  
Debtors Days Days3994 41.2%  
Net fixed assets Rs m116,90450,661 230.8%   
Share capital Rs m3693,000 12.3%   
"Free" reserves Rs m272,16148,808 557.6%   
Net worth Rs m272,53051,808 526.0%   
Long term debt Rs m270,19617,898 1,509.6%   
Total assets Rs m856,26199,897 857.1%  
Interest coverage x1.510.6 13.8%   
Debt to equity ratio x1.00.3 287.0%  
Sales to assets ratio x0.20.4 37.4%   
Return on assets %6.95.2 133.3%  
Return on equity %5.48.7 61.7%  
Return on capital %12.49.6 128.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20012,058 126.1%   
Fx outflow Rs m4,8897,348 66.5%   
Net fx Rs m10,3124,710 218.9%   
CASH FLOW
From Operations Rs m-115,9756,621 -1,751.6%  
From Investments Rs m-8,265-6,840 120.8%  
From Financial Activity Rs m107,525-2,397 -4,485.8%  
Net Cashflow Rs m-16,650-2,612 637.5%  

Share Holding

Indian Promoters % 52.9 40.4 130.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.0 8.4 47.6%  
FIIs % 26.6 10.7 248.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 19.9 82.9%  
Shareholders   93,274 109,995 84.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 13, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS